Multiplex Mutation screening by mass spectrometry: Evaluation of 820 cases from a personalized cancer medicine registry

Journal of Molecular Diagnostics

Volumn 13, Issue 5, 2011, Pages 504-513

  Beadling, Carol ^a,b   Heinrich, Michael C ^a,b   Warrick, Andrea ^b   Forbes, Erin M ^b   Nelson, Dylan ^b   Justusson, Emily ^b   Levine, Judith ^b   Neff, Tanaya L ^b   Patterson, Janice ^b   Presnell, Ajia ^b   McKinley, Arin ^b   Winter, Laura J ^b   Dewey, Christie ^b   Harlow, Amy ^b   Barney, Oscar ^b   Druker, Brian J ^b   Schuff, Kathryn G ^a,b   Corless, Christopher L ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER SCREENING; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; ENDOMETRIUM CANCER; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MASS SPECTROMETRY; MELANOMA; PERSONALIZED MEDICINE; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR GENE;

EID: 82655176916     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.04.003     Document Type: Article

References (65)

1. Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817
2. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349 (Pubitemid 46621810)
3. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: cALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J ClinOncol 2008, 26:5360-5367
4. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-5273
5. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287
6. Carvajal RD, Chapman PB, Wolchok JD, Cane L, Teitcher JB, Lutzky J, Pavlick AC, Bastian BC, Antonescu CR, Schwartz GK: A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009, 27:abstr 9001 27 (No 15S):9001
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480 (Pubitemid 34879334)
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037 (Pubitemid 32267972)
9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042 (Pubitemid 32267973)
10. Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, Kemsley K, Cantarini M, Morris C, Kirkwood J: AZD6244 (ARRY-142886) versus temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol 2008, 26 (No 15S):9033
11. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27 (No 15S):9000
12. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac RS, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051
13. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048 (Pubitemid 350106711)
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small- cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139 (Pubitemid 38637993)
15. Sondak VK Smalley K: Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. Pigment Cell Melanoma Res 2009, 22:386-387
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819
17. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4:e4576
18. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566 (Pubitemid 47206930)
19. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703
20. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721
21. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417
22. Alexis JB, Martinez AE, Lutzky J: An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005, 15:283-285 (Pubitemid 41127464)
23. Eton O, Billings L, Kim K: Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 2004, 22:114-s114s
24. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92:1398-1405 (Pubitemid 40705006)
25. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106:2005-2011 (Pubitemid 43673217)
26. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007, 121:257-264 (Pubitemid 46917693)
27. Curtin JA, Busam K, Pinkel D, Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346 (Pubitemid 46630793)
28. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D: Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/ mucosal type. Mod Pathol 2009, 22:1446-1456
29. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F III, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14:6821-6828
30. Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nose V: Absence of BRAF. NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol 2009, 21:73-79
31. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D: Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol 2009, 578:307-343
32. van den Boom D, Ehrich M: Discovery and identification of sequence polymorphisms and mutations with MALDI-TOF MS. Methods Mol Biol 2007, 366:287-306
33. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue- Geile KL: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010, 10:101
34. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010, 70:5901-5911
35. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4:e7887
36. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA: High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351 (Pubitemid 46328493)
37. Arcila M, Lau C, Nafa K, Ladanyi M: Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011, 13:64-73
38. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM: MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010, 70:6233-6237
39. Cruz F III, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003, 63:5761-5766 (Pubitemid 37187472)
40. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353: 2135-2147 (Pubitemid 41653105)
41. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent- Puig P, Piard F: Mutations in the RAS-MAPK. PI(3)K (phosphatidylinositol- 3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259 (Pubitemid 351542328)
42. Harada K, Hiraoka S, Kato J, Horii J, Fujita H, Sakaguchi K, Shiratori Y: Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 2007, 97:1425-1431 (Pubitemid 350114780)
43. Shinozaki M, Fujimoto A, Morton DL, Hoon DS: Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004, 10:1753-1757 (Pubitemid 38435567)
44. Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML: Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010, 120:409-418
45. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S: Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998, 58:3526-3528 (Pubitemid 28376543)
46. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH: PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006, 12:5932-5935 (Pubitemid 44703751)
47. Moreno-Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T: Low frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin Cancer Res 2006, 12:3865-3866
48. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162 (Pubitemid 350059681)
49. Saegusa M, Hashimura M, Yoshida T, Okayasu I: beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001, 84:209-217 (Pubitemid 32113448)
50. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, Nei T, Kawana K, Kuramoto H, Aburatani H, Yano T, Taketani Y: The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009, 101:145-148
51. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC: PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006, 126:1660-1663
52. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008, 99:1265-1268
53. Omholt K, Platz A, Ringborg U, Hansson J: Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001, 92:839-842 (Pubitemid 32467373)
54. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602
55. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8:3468-3474 (Pubitemid 35340723)
56. Omholt K, Krockel D, Ringborg U, Hansson J: Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 2006, 16:197-200 (Pubitemid 44090052)
57. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R: BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005, 125:312-317 (Pubitemid 41648165)
58. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K: BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003, 9:3362-3368 (Pubitemid 37082731)
59. Lang J, Mackie RM: Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005, 125:575-579
60. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003, 9:6483-6488 (Pubitemid 38031837)
61. Saldanha G, Potter L, Daforno P, Pringle JH: Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006, 12:4499-4505 (Pubitemid 44297798)
62. Henderson YC, Ahn SH, Kang Y, Clayman GL: Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 2008, 14:4908-4914
63. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA: Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009, 15:6008-6017
64. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, Van Der Kwast TH, Zwarthoff EC: FGFR3. HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010, 5:e13821
65. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther 2011, 10:558-565